AbbVie expects $2.7 billion R&D charge in third quarter
Drugmaker AbbVie in a regulatory filing on Friday said it expects third-quarter earnings to include a $2.7 billion charge related to in-process research and development (IPR&D) expenses.
Fiscal Year: January - December
AbbVie Inc. (ABBV), listed on the NYSE, has a market capitalization of $. As of Oct 04, 2025, the stock is trading at $233.91 per share, offering investors a clear view of its current market value. AbbVie Inc. is a prominent player in the industry sector, attracting both institutional and retail investors due to its performance and potential.
With a P/E ratio of 111.38, investors can assess the stock's valuation in comparison to its earnings. A P/E ratio is a crucial indicator for value investors, showing whether the stock is over or undervalued relative to its current earnings. AbbVie Inc. also offers a dividend yield of 2.8%, making it an attractive option for income-focused investors who seek regular dividends.
Our Discounted Cash Flow (DCF) analysis reveals that AbbVie Inc. (ABBV) may be undervalued compared to its intrinsic worth. However, to see the exact DCF fair value, please Login or Upgrade for access.
The proprietary SS Score for AbbVie Inc. is a unique metric that analyzes the company's financial health and growth potential. The score takes into account critical factors such as revenue growth, net income, free cash flow (FCF) compound annual growth rate (CAGR), the trend of shares outstanding, and the debt-to-FCF ratio. This helps investors to make a more informed decision, as an undervalued stock might still have poor financial fundamentals.
To view the detailed SS Score for AbbVie Inc., Login or Upgrade for access.
The Price to Free Cash Flow (P/FCF) ratio for AbbVie Inc. is 22.73, offering insights into how much investors are paying for the company's free cash flow. A lower P/FCF ratio typically suggests that the stock is undervalued, while a higher ratio may indicate overvaluation.
In summary, AbbVie Inc. (ABBV) has shown consistent financial performance, as illustrated by the financial charts above, which track its revenue growth, net income, free cash flow, and shares outstanding over the past several years. These metrics provide investors with key insights into the company's past and projected future performance. Investors should use the SS Score alongside the DCF Fair Value to make better-informed decisions about whether to buy or hold the stock.
*This analysis is for informational purposes only and does not constitute investment advice. Always read the company's 10-K filings and do your own research before making any investment decisions.
Whether AbbVie Inc. (ABBV) is a good stock to buy depends on various factors, including its financial health, market conditions, and your investment strategy. Our analysis indicates that the stock may be undervalued compared to its intrinsic value. However, it is important to assess the SS Score and review the company's fundamentals before making any investment decisions.
The fair value of AbbVie Inc. (ABBV) is determined through our Discounted Cash Flow (DCF) analysis. This value represents the intrinsic worth of the stock based on its expected future cash flows. To view the specific fair value, consider subscribing to our service for complete access.
The SS Score is a proprietary financial quality metric that assesses factors such as revenue growth, net income, free cash flow growth, and debt levels. It helps investors evaluate the overall financial health of AbbVie Inc.. To access the full SS Score, consider upgrading your subscription.
AbbVie Inc. is a significant player in the industry sector, with a market capitalization of $ and a competitive P/E ratio of 111.38. Investors should compare these metrics with industry peers to gauge whether AbbVie Inc. is outperforming or underperforming within its sector.
Drugmaker AbbVie in a regulatory filing on Friday said it expects third-quarter earnings to include a $2.7 billion charge related to in-process research and development (IPR&D) expenses.
AbbVie is outperforming expectations with strong commercial results, pipeline progress, and the legal win that secured Rinvoq's long-term market exclusivity. ABBV has raised the full-year revenue guid...
AbbVie stock (NYSE: ABBV) rallied 11% in a week, largely driven by a key development that boosted the entire sector: Pfizer's agreement to lower its drug prices for Medicaid and a White House decision...
NORTH CHICAGO, Ill. , Oct. 2, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its third-quarter 2025 financial results on Friday, October 31, 2025, before the market opens.
This agreement grants Vizient clients enhanced access to Natrelle®, the broadest selection of breast implant options on the market. IRVINE, Calif.
Expansion increases biologics manufacturing for immunology and oncology medicines Milestone marks progress on AbbVie's long-term commitment to U.S. manufacturing Furthers longstanding commitment to Ab...
– BLA based on data from the global Phase 1/2 CADENZA trial NORTH CHICAGO, Ill. , Sept. 30, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced submission of a new Biologics License Application (...
Tokyo, Japan and Cambridge and London, UK, 30 September 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that it has reached a second important R&D milestone under its mult...
New state-of-the-art active pharmaceutical ingredient (API) facility will manufacture immunology, oncology and neuroscience medicines Facility expected to be fully operational and serving patients by ...
AbbVie said on Monday it would launch its ovarian cancer drug Elahere in the U.K. at a list price equal to that in the U.S.
The list price will be consistent with the United States to reflect the value of the innovation AbbVie is committed to ensuring that developed nations fully recognize the value of our medicines in imp...
AbbVie is rated a strong buy for its strong dividend growth, robust fundamentals, and proven track record as a Dividend King. ABBV offers a compelling mix of a 3% yield and nearly 7% annual historical...
CNBC's “Closing Bell Overtime” team discusses President Trump's plan to impose a 100% tariff on “all any branded or patented Pharmaceutical Product” entering the U.S. with Geoff Meacham of Citi Resear...
Courtney Breen, Bernstein senior analyst, joins 'The Exchange' to discuss the companies exempt from pharma tariffs, the country's with existing trade deals and much more.
John Flavin, Portal Innovations founder and CEO, joins CNBC's 'Squawk on the Street' to discuss the Trump administration's proposed pharmaceutical tariffs, the impact on biotech startups and clinical ...
Submission supported by data from the Phase 3 TEMPO program that demonstrated symptomatic improvement across the Parkinson's disease spectrum Positive results across all three Phase 3 TEMPO trials rei...
Spherix Global Insights finds majority of specialists expect Rinvoq's uptake to accelerate, with potential implications branching to the polymyalgia rheumatica landscape. Spherix Global Insights finds...
New AA (Allergan Aesthetics) Signature™ multimodal treatment approach to be presented at AMWC Dubai following successful launch in 25 countries so far this year. Experts to explore the paradigm shift ...
Income is lagging growth this year. But companies like Seagate, Newmont, Tapestry and CVS offer the best of both worlds: solid dividend yields and strong stock performance.
SKINVIVE ® to launch in 35 additional markets worldwide from September taking the total to 57 international launches in 2025. Research highlights 94% of people want to improve facial skin quality1*, w...
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
The company is dealing with declining sales of its former cash-cow drug Humira.
AbbVie shares rose 4% to a record high on Thursday after the U.S. drugmaker said it expected no generic competition for its blockbuster immunology drug Rinvoq until 2037, a four-year extension, accord...
Below estimates were sourced from SimplyWallSt and are intended for educational purposes only as a baseline for the analysis.
Year | FCF Estimate | % | # Analysts |
---|---|---|---|
2025 | 21.84B | 22.48% | Est @22.5% |
2026 | 25.85B | 18.35% | Analyst x5 |
2027 | 28.42B | 9.95% | Analyst x5 |
2028 | 30.43B | 7.05% | Analyst x4 |
2029 | 32.33B | 6.27% | Analyst x3 |
2030 | 33.51B | 3.63% | Est @3.6% |
2031 | 34.59B | 3.23% | Est @3.2% |
2032 | 35.61B | 2.96% | Est @3.0% |
2033 | 36.59B | 2.76% | Est @2.8% |
2034 | 37.49B | 2.45% | Est @2.5% |
Below are the FCF estimates with the discount factor and the calculated present value with the terminal value that led the results above.
Year | FCF | Discount Factor | PV of Future FCF |
---|---|---|---|
2023A | 22.06B | 1.00 | 22.06B |
2024A | 17.83B | 1.00 | 17.83B |
2025E | 21.84B | 1.07 | 20.33B |
2026E | 25.85B | 1.15 | 22.40B |
2027E | 28.42B | 1.24 | 22.93B |
2028E | 30.43B | 1.33 | 22.85B |
2029E | 32.33B | 1.43 | 22.61B |
2030E | 33.51B | 1.54 | 21.81B |
2031E | 34.59B | 1.65 | 20.96B |
2032E | 35.61B | 1.77 | 20.09B |
2033E | 36.59B | 1.90 | 19.22B |
2034E | 37.49B | 2.05 | 18.33B |
Terminal | 781.43B | 2.05 | 382.06B |
The information given by Studying Stocks and provided in the web and/or mobile applications (Platforms) is only factual information and should not be considered financial advice.
Any information contained in this website has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
When creating an account, you acknowledge that you are:
We retain the right to cancel your account for any reason, or refuse your account creation request.
The information on our Platforms is not comprehensive and is intended to provide a summary of the subject matter covered. While we use all reasonable attempts to ensure the accuracy and completeness of the data and information on our Platforms, to the extent permitted by law, we make no warranty regarding the information on these Platforms. You should monitor any changes to the information contained on these Platforms.
Furthermore we make no commitments in regards to the minimum amount of uptime that our platforms will maintain, although we will make ever reasonable attempt to ensure that the platforms are operational. Therefore, any reference of "latest", "current" and related words about the financial data presented here may not be up to date with the financial markets or represent reality of the information.
We are not liable to you or anyone else if interference with or damage to your computer systems occurs in connection with the use of these Platforms or a linked website. You must take your own precautions to ensure that whatever you select for your use from our Platforms is free of viruses or anything else (such as worms or Trojan horses) that may interfere with or damage the operations of your computer systems.
We may, from time to time and without notice, change or add to the Platforms (including the Terms) or the information, products or services described in it. However, we do not undertake to keep the Platforms updated. We are not liable to you or anyone else if errors occur in the information or the Platforms is not up-to-date.
Our Platforms may contain links to websites operated by third parties. Those links are provided for convenience and may not remain current or be maintained. Unless expressly stated otherwise, we do not endorse and are not responsible for the content on those linked websites and have no control over or rights in those linked websites.
These Platforms are for your personal, non-commercial use only. You may not modify, copy, distribute, transmit, display, perform, reproduce, publish, license, commercially exploit, create derivative works from, transfer, or sell any Content, software, products or services contained within these Platforms. You may not use these Platforms, or any of its Content, to further any commercial purpose, including any advertising or advertising revenue generation activity on your own website.
You must not do any act that we would deem to be inappropriate, is unlawful or is prohibited by any laws applicable to these Platforms, including but not limited to:
If we allow you to post any information to our Platforms, we have the right to take down this information at our sole discretion and without notice.
To the maximum extent permitted by law, we make no warranties or representations about these Platforms or the Content, including but not limited to warranties or representations that they will be complete, accurate or up-to-date, that access will be uninterrupted or error-free or free from viruses, or that these Platforms will be secure.
We reserve the right to restrict, suspend or terminate without notice your access to these Platforms, any Content, or any feature of these Platforms at any time without notice and we will not be responsible for any loss, cost, damage or liability that may arise as a result.
To the maximum extent permitted by law, in no event shall we be liable for any direct and indirect loss, damage or expense – irrespective of the manner in which it occurs – which may be suffered due to your use of our Platforms and/or the information or materials contained on it, or as a result of the inaccessibility of these Platforms and/or the fact that certain information or materials contained on it are incorrect, incomplete or not up-to-date.
This website utilises cookies. If you do not have cookies enabled in your web browser some functions of the site may not work as intended.